Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAE609 in Induced Blood Stage Malaria
NCT02543086Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jul 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cipargamin in Plasmodium falciparum malaria (2 arms), sponsored by Novartis. Primary endpoint: Parasitic count in blood by Polymerase Chain Reaction at 36 days. Started Jul 2015; status: terminated.
02
Drugs
cipargamin
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT02543086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02543086.